Did You Buy These Stocks?

(RTTNews) - Biotech stocks can be risky as their fortunes depend on two key events namely clinical trial results and FDA decisions. Nevertheless, the returns can be impressive when the stocks are bought and sold at the right time.

What follows is a bunch of our biotech stock picks of 2013 that continue to trade up a minimum 100 percent and above since we profiled them on our site. The near-term catalysts of the highlighted stocks, if any, are also mentioned in this report.

Alimera Sciences Inc. (ALIM) was trading around $1.69 when we alerted readers to the stock in January. It went on to touch a high of $5.69 in June, which was a gain of over 236%, had you bought the stock in January.

ALIM closed Thursday's trading at $3.83, down 2.79%.

Raptor Pharmaceutical Corp. (RPTP), which was at $6.23 when it was profiled on our site in January, touched a 52-week high of $14.90 on September 5, implying a gain of 139%.

Earlier this week, the European Commission approved PROCYSBI, the company's drug for the management of nephropathic cystinosis, in the European Union. The drug was approved by FDA in April of this year.

RPTP closed Thursday's trading 1.05% higher at $14.50.

Galectin Therapeutics (GALT) was trading as low as $2.46 when we alerted readers to the stock in January. The stock, which has had a steady run since then, touched a 52-week high of $13.21 on September 12, reflecting a whopping a 437% return.

The company's lead compound for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis is GR-MD-02, which is under phase I testing. Top line clinical results from this study are expected sometime late in 2013 or early 2014.

GALT closed Thursday's trading at $9.19, down 1.18%.

Insmed Inc. (INSM) was trading at $5.83 when we alerted readers to the stock in February. In the months that followed, INSM had a stellar run and went on to touch a 52-week high of $16.50 on September 16, returning a gain of 183%.

The company's lead product candidate is ARIKACE, an inhaled liposomal formulation of the commonly used antibiotic Amikacin.

Insmed expects ARIKACE EMA filing in Cystic Fibrosis in the first half of 2014, and results of the U.S. phase II clinical trial in patients with non-tuberculous mycobacterial lung disease to be reported in Q1, 2014.

INSM closed Thursday's trading 1.49% higher at $15.63.

Inovio Pharmaceuticals Inc. (INO) was trading at $0.54 when it was profiled on our site in March, and it touched a high of $3.03 on August 6, representing a gain of 461%.

Last week, Inovio signed a deal with Roche to develop and commercialize prostate cancer and hepatitis B immunotherapy products.

INO closed Thursday's trading at $2.33, down 1.27%.

Immunomedics Inc. (IMMU) was trading at $2.50 when we alerted readers to the stock in May, and it went on to touch a 52-week high of $6.91 on July 16. This represents a return of 176% in just 2.5 months

A phase III registration trial of Clivatuzumab tetraxetan in patients with pancreatic cancer who have received at least 2 prior therapies is planned for the end of calendar year 2013 or the beginning of 2014.

IMMU closed Thursday's trading at $5.99, up 0.67%.

BioCryst Pharmaceuticals Inc. (BCRX) was trading as low as $1.71 when we alerted readers to the stock in May. The stock has had a nice run since then and it touched a 52-week high of $7.67 on September 17, which reflects a gain of 348%.

BCRX closed Thursday's trading at $6.79, up 0.74%.

Rockwell Medical (RMTI), which was trading at $3.45 when we alerted readers to the stock in May, touched a high of $11.80 on September 16, implying a gain of 242%.

The company's lead product candidate is Triferic, an iron-delivery drug, which is intended for treating iron deficiency in chronic kidney disease patients receiving hemodialysis.

Rockwell Medical has successfully completed two phase III efficacy studies to provide clinical data required for filing a New Drug Application with the FDA.

RMTI closed Thursday's trading 3.69% down at $9.39.

Arrowhead Research Corp. (ARWR) was trading at $2.22 when it was profiled on our site in June. The stock touched a high of $4.99 on September 16, which represents a gain of over 124%.

ARWR closed Thursday's trading at $4.75, up 2.15%.

Catalyst Pharmaceutical Partners Inc. (CPRX) was trading around $1.37 when we alerted readers to the stock last month. The stock touched a new 52-week high of $2.99 yesterday before closing at $2.86. The 52-week high price represents a gain of $118% had you bought the stock last month.

The company's lead drug candidate is Firdapse, which is under phase III testing for Lambert-Eaton Myasthenic Syndrome, a rare neuromuscular, autoimmune disorder frequently associated with small cell lung cancer.

Enrollment in the phase III trial is scheduled for completion in the fourth quarter of 2013 and top-line results from the double-blind portion of the trial are expected to be reported during the second quarter of 2014.

Keep a watch on CYCC, the stock we alerted as recently as August 29.

Visit Emerging Biostocks (http://www.rttnews.com/Products/EBSService.aspx) for a complete list of our biotech stock picks.